Compare Mesoblast Limited (MESO) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Abrdn Physical Platinum Shares ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Abrdn Physical Platinum Shares ETF trades at $14.82. The key difference: Mesoblast Limited is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| MESO | PPLT | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $20.96 | $25.23 |
52-Week Low | $12.88 | $11.78 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.47, down 0.21% on the day, amid a predominantly bearish technical signal with moving averages indicating strong selling pressure. The fund, which holds physical platinum, has seen significant volatility, with recent news highlighting its underperformance compared to gold and silver. A 10-for-1 stock split is scheduled for May 2026, which will adjust the share count without altering the fund's net asset value.
The outlook for PPLT is cautious, with technical indicators leaning bearish and sentiment mixed after a substantial rally. Investment opportunity hinges on a potential catch-up trade if platinum gains favor, but risks include commodity price swings and the ETF's lack of dividends, which may deter income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
